The Korea Food and Drug Administration (KFDA, now formally known as MFDS — Ministry of Food and Drug Safety) is the Korea Południowan regulatory authority responsible for approving pharmaceutical products including botulinum toxin formulations. KFDA approval represents a rigorous safety and efficacy evaluation process comparable to the EMA in Europe and FDA in the United States.
What KFDA Approval Means
KFDA-approved botulinum toxin products must meet strict standards for manufacturing quality, potency consistency, sterility, and clinical evidence. Manufacturers must maintain cGMP (current Good Manufacturing Practice) certification and submit to regular facility inspections. For European practitioners, KFDA approval provides meaningful assurance of product quality and safety.
KFDA-Approved Korean Toxins Available in Europe
Botulax — Hugel Inc. Flagship Korean toxin, widely distributed globally, consistent clinical track record.
Nabota — Daewoong Pharmaceutical. Unique dual KFDA and US FDA approval. High purity Hi-Pure technology.
Liztox — Huons Global. Cost-effective KFDA-approved option.
Metox — Medytox Inc. From Korea's botulinum toxin pioneer.
Innotox — Medytox Inc. World's first liquid pre-diluted toxin. KFDA approved.
European Regulatory Considerations
While KFDA approval validates product quality and manufacturing, practitioners must ensure compliance with national regulations in their jurisdiction. Botulinum toxin is a prescription medicine in most EU member states. Import and use regulations vary by country.
Produkty Zatwierdzone przez KFDA
All our botulinum toxins are KFDA approved. Licensed professionals only.
View Toxins